Irritable Bowel Syndrome (IBS)

FDA Permits Restricted Use of Zelnorm for Qualifying Patients

The U.S. Food and Drug Administration announced that it is permitting the restricted use of Zelnorm (tegaserod maleate) under a treatment investigational new drug (IND) protocol to treat irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC) in women younger than 55 who meet specific guidelines.

For more information about common digestive disorders please see the following:

• American Liver Foundation (ALF)
  75 Maiden Lane, Suite 603
  New York, NY 10038–4810
  Phone: 1–800–GO–LIVER (465–4837),
  1–888–4HEP–USA (443–7872),
  or 212–668–1000
  Fax: 212–483–8179
  Email: info@liverfoundation.org
  Internet: www.liverfoundation.org
• Celiac Disease Foundation